Insider · CIK 0001172252
SCHIFF ANDREW N
Reports to the SEC for 21 companies · BOSTON, MA
Transactions
50
Companies
21
Filings
9
CIK
0001172252
Forms 4 and 5
Insider transactions
| Date | Company | Value |
|---|---|---|
| 2026-06-11 | GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2026-06-05 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2026-06-05 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2026-06-04 | ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2026-06-04 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award | — |
| 2025-06-13 | GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2025-06-06 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2025-06-06 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2025-06-05 | ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2025-06-05 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award | — |
| 2024-06-12 | GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2024-06-06 | ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2024-06-06 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award | — |
| 2024-06-01 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2024-06-01 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2023-06-14 | GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2023-06-02 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2023-06-02 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2023-06-01 | ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2023-06-01 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award | — |
| 2022-11-14 | ACRSAclaris Therapeutics, Inc.S Sale | −$23.4K |
| 2022-11-11 | ACRSAclaris Therapeutics, Inc.S Sale | −$702K |
| 2022-11-10 | ACRSAclaris Therapeutics, Inc.S Sale | −$194K |
| 2022-10-26 | ACRSAclaris Therapeutics, Inc.S Sale | −$247K |
| 2022-10-25 | ACRSAclaris Therapeutics, Inc.S Sale | −$205K |
| 2022-10-24 | ACRSAclaris Therapeutics, Inc.S Sale | −$249K |
| 2022-10-18 | ACRSAclaris Therapeutics, Inc.S Sale | −$542K |
| 2022-10-17 | ACRSAclaris Therapeutics, Inc.S Sale | −$320K |
| 2022-10-07 | ACRSAclaris Therapeutics, Inc.S Sale | −$118K |
| 2022-10-06 | ACRSAclaris Therapeutics, Inc.S Sale | −$626K |
| 2022-10-04 | ACRSAclaris Therapeutics, Inc.S Sale | −$123K |
| 2022-06-17 | ACRSAclaris Therapeutics, Inc.S Sale | −$296K |
| 2022-06-15 | GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2022-06-03 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2022-06-03 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2022-06-02 | ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2022-06-02 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award | — |
| 2021-06-23 | GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2021-06-03 | ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2021-06-03 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award | — |
| 2020-06-06 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2020-06-06 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2020-06-04 | ACRSAclaris Therapeutics, Inc. · Option Grant (right to buy)A Award | — |
| 2020-03-02 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2020-03-02 | ACRSAclaris Therapeutics, Inc. · Restricted stock unitsA Award | — |
| 2020-03-02 | ACRSAclaris Therapeutics, Inc. · Restricted stock unitsM Exercise/Conversion | — |
| 2019-06-06 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award | — |
| 2018-06-07 | ACRSAclaris Therapeutics, Inc. · Stock Option (right to buy)A Award | — |
| 2017-08-16 | ACRSAclaris Therapeutics, Inc.P Purchase | +$2.5M |
| 2017-08-09 | ACRSAclaris Therapeutics, Inc. · Stock Option (right to buy)A Award | — |
Recent filings
- 4SCHIFF ANDREW N0001193125-26-269365SEC(opens sec.gov)
- 4SCHIFF ANDREW N0001172252-26-000002SEC(opens sec.gov)
- 4SCHIFF ANDREW N0000950170-25-086699SEC(opens sec.gov)
- 4SCHIFF ANDREW N0001415889-25-016252SEC(opens sec.gov)
- 4SCHIFF ANDREW N0000950170-24-073064SEC(opens sec.gov)
- 4SCHIFF ANDREW N0001415889-24-016193SEC(opens sec.gov)
- 4SCHIFF ANDREW N0001415889-24-015360SEC(opens sec.gov)
- 4SCHIFF ANDREW N0001209191-23-037352SEC(opens sec.gov)
- 4SCHIFF ANDREW N0001209191-23-034411SEC(opens sec.gov)
Companies
- Aclaris Therapeutics, Inc.DirectorACRS
- Adams Respiratory Therapeutics, Inc.Director
- ADMA BIOLOGICS, INC.10% OwnerADMA
- AGILE THERAPEUTICS INC10% Owner
- Aravive, Inc.10% Owner
- ASENSUS SURGICAL, INC.Former 10% Owner
- BARRIER THERAPEUTICS INCDirector
- Cidara Therapeutics, Inc.10% OwnerCDTX
- Durata Therapeutics, Inc.10% Owner
- Elevation Oncology, Inc.10% Owner
- Esperion Therapeutics, Inc.10% OwnerESPR
- Loxo Oncology, Inc.10% Owner
- MELINTA THERAPEUTICS, INC. /NEW/10% Owner
- Monte Rosa Therapeutics, Inc.DirectorGLUE
- MYOGEN INCDirector
- Syros Pharmaceuticals, Inc.10% Owner
- T2 Biosystems, Inc.10% Owner
- ViewRay, Inc.10% Owner
- Viracta Therapeutics, Inc.10% OwnerVIRX
- Zeltiq Aesthetics IncDirector, 10% Owner
- Zosano Pharma Corp10% Owner
Address
MONTE ROSA THERAPEUTICS, INC. 321 HARRISON AVENUE, SUITE 900
BOSTON, MA, 02118